Role of bile acids in cirrhosis-related cardiomyopathy
10.3969/j.issn.1001-5256.2022.10.035
- VernacularTitle:胆汁酸在肝硬化心肌病中的作用
- Author:
Shiyang LIANG
1
;
Qiang LIN
1
;
Junliang SONG
1
;
Jingjie WANG
1
Author Information
1. Department of Gastroenterology, Tangdu Hospital, The Air Force Military Medical University, Xi'an 710038, China
- Publication Type:Reviews
- Keywords:
Liver Cirrhosis;
Cardiomyopathies;
Bile Acids and Salts
- From:
Journal of Clinical Hepatology
2022;38(10):2383-2386
- CountryChina
- Language:Chinese
-
Abstract:
Liver cirrhosis-related cardiomyopathy (CCM) is a common and easily overlooked complication associated with liver cirrhosis. Because of the high incidence and impact on success of the liver transplantation and the transcarotid intrahepatic portosystemic shunt surgery, it has attracted the attention of researchers in the field recently. Liver cirrhosis patients have liver morphological alterations, which result in increased serum level of total bile acids and changes in bile acid composition. The increased bile acid concentrations are cardiotoxic and change cardiac functions. This study discussed and summarized recent advancements in the role of bile acids in cirrhosis-related cardiomyopathy in three aspects, i.e., changes in bile acid metabolism in liver cirrhosis patients, effects of bile acid on changes in cardiac functions, and ursodeoxycholic acid as a potential therapeutic agent for CCM. This review expects to provide novel approaches for future prevention and treatment of CCM.
